Cargando…

Test accuracy of faecal calprotectin for inflammatory bowel disease in UK primary care: a retrospective cohort study of the THIN data

OBJECTIVE: To estimate the test accuracy of faecal calprotectin (FC) for inflammatory bowel disease (IBD) in the primary care setting using routine electronic health records. DESIGN: Retrospective cohort test accuracy study. SETTING: UK primary care. PARTICIPANTS: 5970 patients (≥18 years) without a...

Descripción completa

Detalles Bibliográficos
Autores principales: Freeman, Karoline, Taylor-Phillips, Sian, Willis, Brian H, Ryan, Ronan, Clarke, Aileen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903095/
https://www.ncbi.nlm.nih.gov/pubmed/33619196
http://dx.doi.org/10.1136/bmjopen-2020-044177
_version_ 1783654669488226304
author Freeman, Karoline
Taylor-Phillips, Sian
Willis, Brian H
Ryan, Ronan
Clarke, Aileen
author_facet Freeman, Karoline
Taylor-Phillips, Sian
Willis, Brian H
Ryan, Ronan
Clarke, Aileen
author_sort Freeman, Karoline
collection PubMed
description OBJECTIVE: To estimate the test accuracy of faecal calprotectin (FC) for inflammatory bowel disease (IBD) in the primary care setting using routine electronic health records. DESIGN: Retrospective cohort test accuracy study. SETTING: UK primary care. PARTICIPANTS: 5970 patients (≥18 years) without a previous IBD diagnosis and with a first FC test between 1 January 2006 and 31 December 2016. We excluded multiple tests and tests without numeric results in units of µg/g. INTERVENTION: FC testing for the diagnosis of IBD. Disease status was confirmed by a recorded diagnostic code and/or a drug code of an IBD-specific medication at three time points after the FC test date. MAIN OUTCOME MEASURES: Sensitivity, specificity, and positive and negative predictive values for the differential of IBD versus non-IBD and IBD versus irritable bowel syndrome (IBS) at the 50 and 100 µg/g thresholds. RESULTS: 5970 patients met the inclusion criteria and had at least 6 months of follow-up data after FC testing. 1897 had an IBS diagnosis, 208 had an IBD diagnosis, 31 had a colorectal cancer diagnosis, 80 had more than one diagnosis and 3754 had no subsequent diagnosis. Sensitivity, specificity, and positive and negative predictive values were 92.9% (88.6% to 95.6%), 61.5% (60.2% to 62.7%), 8.1% (7.1% to 9.2%) and 99.6% (99.3% to 99.7%), respectively, at the threshold of 50 µg/g. Raising the threshold to 100 µg/g missed less than 7% additional IBD cases. Longer follow-up had no effect on test accuracy. Overall, uncertainty was greater for specificity than sensitivity. General practitioners’ (GPs’) referral decisions did not follow the anticipated clinical pathways in national guidance. CONCLUSIONS: GPs can be confident in excluding IBD on the basis of a negative FC test in a population with low pretest risk but should interpret a positive test with caution. The applicability of national guidance to general practice needs to be improved.
format Online
Article
Text
id pubmed-7903095
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-79030952021-03-09 Test accuracy of faecal calprotectin for inflammatory bowel disease in UK primary care: a retrospective cohort study of the THIN data Freeman, Karoline Taylor-Phillips, Sian Willis, Brian H Ryan, Ronan Clarke, Aileen BMJ Open General practice / Family practice OBJECTIVE: To estimate the test accuracy of faecal calprotectin (FC) for inflammatory bowel disease (IBD) in the primary care setting using routine electronic health records. DESIGN: Retrospective cohort test accuracy study. SETTING: UK primary care. PARTICIPANTS: 5970 patients (≥18 years) without a previous IBD diagnosis and with a first FC test between 1 January 2006 and 31 December 2016. We excluded multiple tests and tests without numeric results in units of µg/g. INTERVENTION: FC testing for the diagnosis of IBD. Disease status was confirmed by a recorded diagnostic code and/or a drug code of an IBD-specific medication at three time points after the FC test date. MAIN OUTCOME MEASURES: Sensitivity, specificity, and positive and negative predictive values for the differential of IBD versus non-IBD and IBD versus irritable bowel syndrome (IBS) at the 50 and 100 µg/g thresholds. RESULTS: 5970 patients met the inclusion criteria and had at least 6 months of follow-up data after FC testing. 1897 had an IBS diagnosis, 208 had an IBD diagnosis, 31 had a colorectal cancer diagnosis, 80 had more than one diagnosis and 3754 had no subsequent diagnosis. Sensitivity, specificity, and positive and negative predictive values were 92.9% (88.6% to 95.6%), 61.5% (60.2% to 62.7%), 8.1% (7.1% to 9.2%) and 99.6% (99.3% to 99.7%), respectively, at the threshold of 50 µg/g. Raising the threshold to 100 µg/g missed less than 7% additional IBD cases. Longer follow-up had no effect on test accuracy. Overall, uncertainty was greater for specificity than sensitivity. General practitioners’ (GPs’) referral decisions did not follow the anticipated clinical pathways in national guidance. CONCLUSIONS: GPs can be confident in excluding IBD on the basis of a negative FC test in a population with low pretest risk but should interpret a positive test with caution. The applicability of national guidance to general practice needs to be improved. BMJ Publishing Group 2021-02-22 /pmc/articles/PMC7903095/ /pubmed/33619196 http://dx.doi.org/10.1136/bmjopen-2020-044177 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.
spellingShingle General practice / Family practice
Freeman, Karoline
Taylor-Phillips, Sian
Willis, Brian H
Ryan, Ronan
Clarke, Aileen
Test accuracy of faecal calprotectin for inflammatory bowel disease in UK primary care: a retrospective cohort study of the THIN data
title Test accuracy of faecal calprotectin for inflammatory bowel disease in UK primary care: a retrospective cohort study of the THIN data
title_full Test accuracy of faecal calprotectin for inflammatory bowel disease in UK primary care: a retrospective cohort study of the THIN data
title_fullStr Test accuracy of faecal calprotectin for inflammatory bowel disease in UK primary care: a retrospective cohort study of the THIN data
title_full_unstemmed Test accuracy of faecal calprotectin for inflammatory bowel disease in UK primary care: a retrospective cohort study of the THIN data
title_short Test accuracy of faecal calprotectin for inflammatory bowel disease in UK primary care: a retrospective cohort study of the THIN data
title_sort test accuracy of faecal calprotectin for inflammatory bowel disease in uk primary care: a retrospective cohort study of the thin data
topic General practice / Family practice
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903095/
https://www.ncbi.nlm.nih.gov/pubmed/33619196
http://dx.doi.org/10.1136/bmjopen-2020-044177
work_keys_str_mv AT freemankaroline testaccuracyoffaecalcalprotectinforinflammatoryboweldiseaseinukprimarycarearetrospectivecohortstudyofthethindata
AT taylorphillipssian testaccuracyoffaecalcalprotectinforinflammatoryboweldiseaseinukprimarycarearetrospectivecohortstudyofthethindata
AT willisbrianh testaccuracyoffaecalcalprotectinforinflammatoryboweldiseaseinukprimarycarearetrospectivecohortstudyofthethindata
AT ryanronan testaccuracyoffaecalcalprotectinforinflammatoryboweldiseaseinukprimarycarearetrospectivecohortstudyofthethindata
AT clarkeaileen testaccuracyoffaecalcalprotectinforinflammatoryboweldiseaseinukprimarycarearetrospectivecohortstudyofthethindata